On one side, pharmaceutical companies are pushing GLP-1 receptor agonists like semaglutide as the only solution for obesity
(And if medication isnt the right toolbecause of anatomy, symptoms, or other issueswell tell you that too, and discuss other options.) Why JourneyLite is different: medical + surgical expertise in one program A lot of online platforms can prescribe a medicationbut they cant offer the full spectrum of obesity care
Collagen can complement a GLP-1 protocol for its protein content and gut-supportive properties, but it is not a substitute for targeted GLP-1 activation
However, this landscape shifted dramatically in late 2025: the Trump administration negotiated deals with Novo Nordisk and Eli Lilly to offer Wegovy and Zepbound at $245/month for Medicare and Medicaid, and CMS launched the BALANCE Model to begin Medicare Part D coverage of GLP-1s for obesity starting in 2027 (with a bridge demonstration in mid-2026) ( [5] )
Scientists commonly use it in controlled laboratory environments to better understand how peptides interact with various biological systems